Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting
Open Access
- 8 January 2013
- journal article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 13 (1), 9
- https://doi.org/10.1186/1471-2334-13-9
Abstract
Background Injection drug users (IDUs) represent a significant proportion of patients with chronic hepatitis C (CHC). The low treatment uptake among these patients results in a low treatment effectiveness and a limited public health impact. We hypothesised that a general practitioner (GP) providing an opioid maintenance treatment (OMT) for addicted patients can achieve CHC treatment and sustained virological response rates (SVR) comparable to patients without drug dependency. Methods Retrospective patient record analysis of 85 CHC patients who received OMT for more than 3 months in a single-handed general practice in Zurich from January 1, 2002 through May 31, 2008. CHC treatment was based on a combination with pegylated interferon and ribavirin. Treatment uptake and SVR (undetectable HCV RNA 6 months after end of treatment) were assessed. The association between treatment uptake and patient characteristics was investigated by multiple logistic regression. Results In 35 out of 85 CHC patients (52 males) with a median (IQR) age of 38.8 (35.0-44.4) years, antiviral therapy was started (41.2%). Median duration (IQR) of OMT in the treatment group was 55.0 (35.0-110.1) months compared to the group without therapy 24.0 (9.8-46.3) months (p<0.001). OMT duration remained a significant determinant for treatment uptake when controlled for potential confounding. SVR was achieved in 25 out of 35 patients (71%). Conclusion In addicted patients a high CHC treatment and viral eradication rate in a primary care setting in Switzerland is feasible. Opioid substitution seems a beneficial framework for CHC care in this “difficult to treat” population.This publication has 29 references indexed in Scilit:
- Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end‐points in clinical trialsAddiction, 2011
- Curing hepatitis C with pills: a step toward global controlThe Lancet, 2010
- Determinants of successful chronic hepatitis C case finding among patients receiving opioid maintenance treatment in a primary care settingAddiction, 2009
- Predictors of antiviral treatment initiation in hepatitis C virus‐infected patients: a Danish cohort studyJournal of Viral Hepatitis, 2009
- Public health impact of antiviral therapy for hepatitis C in the United StatesHepatology, 2009
- Swiss Multicenter Study Evaluating the Efficacy, Feasibility and Safety of Peginterferon-Alfa-2a and Ribavirin in Patients with Chronic Hepatitis C in Official Opiate Substitution ProgramsDigestion, 2008
- Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in Methadone Maintenance Patients: Randomized Comparison of Direct Observed Therapy and Self-AdministrationThe American Journal of Gastroenterology, 2008
- The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort studyAddiction, 2008
- Cohort Profile: The Swiss Hepatitis C Cohort Study (SCCS)International Journal of Epidemiology, 2007
- Hepatitis C Virus and Liver TransplantationClinics in Liver Disease, 2006